Tumor tissue editing provides the chance for reprogramming tumor systems functions towards biological hallmarks associated with tumor growth control and systematically expands a novel range of application for classic targeted therapies, either by targeting frequently overexpressed targets in tumor tissues, such as immune checkpoints, mitogen-activated protein kinase kinase MEK, mTor etc. or classic targets selected according to molecular-genetic aberrations in tumor cells (28, 31, 32). This evidence concerns the gene WNK2 and neoplasm.